LEADER 01823nam 22005774a 450 001 9910781348903321 005 20230721010212.0 035 $a(CKB)2550000000035434 035 $a(OCoLC)732955758 035 $a(CaPaEBR)ebrary10430424 035 $a(SSID)ssj0000553431 035 $a(PQKBManifestationID)11348108 035 $a(PQKBTitleCode)TC0000553431 035 $a(PQKBWorkID)10506717 035 $a(PQKB)10484803 035 $a(MiAaPQ)EBC3016862 035 $a(Au-PeEL)EBL3016862 035 $a(CaPaEBR)ebr10430424 035 $a(EXLCZ)992550000000035434 100 $a20081210d2009 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$a"I've been black in two countries"$b[electronic resource] $eBlack Cuban views on race in the US /$fMichelle A Hay 210 $aEl Paso $cLFB Scholarly Pub.$d2009 215 $a1 online resource (257 p.) 225 1 $aThe new Americans 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a1-59332-335-2 320 $aIncludes bibliographical references (p. 227-244) and index. 410 0$aNew Americans (LFB Scholarly Publishing LLC) 606 $aCubans$zUnited States 606 $aBlack people$zCuba 606 $aRacism$zUnited States 606 $aAfrican Americans$xRelations with Cubans 607 $aUnited States$xRace relations 615 0$aCubans 615 0$aBlack people 615 0$aRacism 615 0$aAfrican Americans$xRelations with Cubans. 676 $a305.8968/7291073 700 $aHay$b Michelle A.$f1960-$01528007 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910781348903321 996 $a"I've been black in two countries"$93771400 997 $aUNINA LEADER 05635nam 2200469z- 450 001 9910220038303321 005 20210211 035 $a(CKB)3800000000216394 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/46423 035 $a(oapen)doab46423 035 $a(EXLCZ)993800000000216394 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aEngineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines 210 $cFrontiers Media SA$d2017 215 $a1 online resource (377 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-051-1 330 $aPlant gene transfer achieved in the early '80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the "green biofactory" implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the "plant factory" attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. "Farming for Pharming" biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries.Plant gene transfer achieved in the early '80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the "green biofactory" implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the "plant factory" attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. "Farming for Pharming" biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries. 606 $aBiotechnology$2bicssc 610 $aBiobetter 610 $abiopharmaceuticals 610 $aGenetic Engineering 610 $aMetabolic Engineering 610 $aPlant factory 610 $aplant molecular farming 610 $arecombinant protein 610 $atransient expression 615 7$aBiotechnology 700 $aDomenico De Martinis$4auth$01305924 702 $aRybicki$b Edward P$4auth 702 $aEugenio Benvenuto$4auth 702 $aRosella Franconi$4auth 702 $aKazuhito Fujiyama$4auth 906 $aBOOK 912 $a9910220038303321 996 $aEngineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines$93028023 997 $aUNINA